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Abstract: Background. Liver diseases are leading causes of death in HIV-positive persons since the
widespread use of combination antiretroviral treatment (ART). Most of these deaths are due to hepatitis
C (HCV) or B (HBV) virus co-infections. Little is known about other causes. Prolonged exposure to
some antiretroviral drugs might increase hepatic mortality.Methods. All patients of the Data Collection
on Adverse Events of Anti-HIV Drugs (D:A:D) study without HCV or HBV co-infection were prospec-
tively followed from date of entry until death, or last follow-up. In patients with liver-related death,
clinical charts were reviewed using a structured questionnaire.Results. We followed 22,910 participants
without hepatitis virus co-infection for 114,478 person-years. There were 12 liver-related deaths (inci-
dence, 0.10/1000 person-years); 7 because of severe alcohol use and 5 due to established ART-related
toxicity. The rate of ART-related deaths in treatment-experienced persons was 0.04 (95% CI 0.01, 0.10)
per 1000 person-years.Conclusions. We found a low incidence of liver-related deaths in HIV-infected
persons without HCV or HBV co-infection. Liver-related mortality because of ART-related toxicity was
rare.
DOI: 10.1093/cid/cis919
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Table 1: Characteristics of D:A:D study participants without HCV or HBV co-infection at study entry. 
 
Total of participants n 22,910 
Male gender n (%) 16737 (73.1) 
Age (years) median (IQR) 38 (32, 46) 
Period of D:A:D cohort registration, n (%) ≤2002 11896 (51.9) 
 2003-2006 7060 (30.8) 
 2007-2009 3954 (17.3) 
Duration of D:A:D cohort follow-up median (IQR) 4.9 (2.2, 8.3) 
Ethnicity, n (%) white 10827 (47.3) 
 black 1762 (7.7) 
 other 499 (2.2) 
 unknown 9817 (42.9) 
Mode of HIV transmission, n (%) heterosexual 9472 (41.3) 
 homosexual 11430 (49.9) 
 IDU 404 (1.8) 
 other/unknown 1604 (7.0) 
Year of first HIV diagnosis median (IQR) 1999 (1994, 2004) 
BMI (kg/m2), n (%) <18 621 (2.7) 
 >18, <26 13228 (57.7) 
 >26, <30 2618 (11.4) 
 >30 902 (3.9) 
 Unknown 5541 (24.2) 
Diabetes mellitus n (%) 597 (2.6) 
Smoking status, n (%) current  7014 (30.6) 
 former 4715 (20.6) 
 never 6788 (29.6) 
 unknown 4393 (19.2) 
CD4 cells/µL median (IQR) 410 (250, 595) 
 n (%) <200 3837 (17.9) 
Previous clinical AIDS n (%) 5176 (22.6) 
Cumulative ART exposure (years) median (IQR) 0.9 (0.0, 3.5) 
Cumulative NRTI exposure (years) median (IQR) 0.8 (0.0, 3.5) 
Cumulative PI exposure (years) median (IQR) 0.0 (0.0, 2.1) 
Cumulative NNRTI exposure (years) median (IQR) 0.0 (0.0, 0.3) 
Treatment status, n (%) naïve 8724 (38.1) 
 interruption 1072 (4.7) 














Table 2: Clinical description of HIV-positive patients without HCV or HBV infection and liver-related death. 
 

















       BL last BL last  BL last  
1 Alcohol 2003 esophageal varices, ascites M 55 1984 420 350 <50 5.37 yes 5.7 7.4  
2 Alcohol 2005 nor reported M 38 1988 322 137 <50 4.08 yes 6.9 11.9  
3 Alcohol 2005 splenomegaly M 34 1991 174 236 3.45 <50 yes 6.3 11.7 Hemochromatosis 




M 57 1991 640 350 <50 <50 yes 3.8 4.3  
5 Alcohol 2003 not reported M 40 1986 297 242 4.20 5.00 no 8.5 10.9  
6 Alcohol 2007 splenomegaly, ascites M 35 1995 375 311 3.40 4.11 no 4.4 8.6  





F 34 2000 405 247 4.18 5.62 no 0 0  




M 56 1990 114 114 <50 1.70 no 8.0 8.4 NCPH, ddI 
9 ART 2001 splenomegaly, encephalopathy M 82 1994 437 437 1.94 1.99 no 5.6 6.1 Lactic acidosis: ddI, d4T 
10 ART 2000 ascites F 46 1993 1080 1080 <50 <50 yes 3.4 3.5 Hypersens: NVP 





M 44 1996 309 327 3.73 4.66 yes 5.4 9.1 Lactic acidosis: DDI, D4T, metformin 





M 54 1993 175 339 3.63 3.48 no 5.5 6.6 NCPH, ddI 
 
* Log10 copies/ml or below 50 HIV RNA copies/ml 
Abbreviations: ART, antiretroviral therapy. BL, baseline. ddI, didanosine. D4T, stavudine. EFV, efavirenz. F, female. HCC, hepatocellular carcinoma. Hypersens, 












Table 3: Comparison of characteristics of HCV- and HBV-seronegative patients with liver-







No. of patients (%) 12 (100) 1047 (100)  
Male gender  n (%) 10 (83.3) 876 (83.7) 1.00 
Age (years)  median (IQR) 45 (36, 55) 47 (38, 57) 0.74 
Year of first HIV diagnosis  median (IQR) 92 (89, 94) 95 (90, 00) 0.05 
Date of D:A:D cohort registration,  <2002 12 (100.0) 793 (75.7) 0.15 
 2003-2006 0  216 (20.6)  
 2007-2009 0 38 (3.6)  
At baseline    
Exposure to ART, years median (IQR) 5.5 (4.1, 6.6) 2.8 (0.1, 5.2) 0.008 
Treatment status, n(%) naive 1 (8.3) 238 (22.7) 0.23 
 interruption 0 (-) 84 (8.0)  
 on ART 11 (91.7) 725 (69.3)  
At last visit    
Nadir CD4 cells/µL  median (IQR) 97 (56, 171) 70 (16, 165) 0.50 
Peak HIV-1 RNA (log10copies/ml) 
 median (IQR)
5.2 (4.9, 5.6) 5.3 (4.7, 5.8) 0.45 
Previous clinical AIDS n (%) 6 (50.0) 688 (65.7) 0.40 
Cumulative ART exposure     
Any, years median (IQR) 7.9 (5.2, 10.0) 5.6 (1.5, 8.9) 0.14 
NRTIs, years median (IQR) 7.9 (5.2, 10.0) 5.4 (1.5, 8.6) 0.11 
NNRTIs, years median (IQR) 0.9 (0.0, 1.6) 0.6 (0.0, 2.2) 0.98 
PIs, years median (IQR) 3.5 (0.2, 6.8) 2.7 (0.3, 5.1) 0.68 
Current treatment status, n (%) naive 1 (8.3) 66 (6.3) 0.75 
 interruption 3 (25.0) 370 (35.3)  
 on ART 8 (66.7) 611 (58.4)  
 
*Death from other causes, n (%): AIDS  376 (35.9), cardiovascular disease 116 (11.1), non-AIDS 
malignancies 149 (14.2), other causes 315 (30.1), unknown causes 91 (8.7). 
Abbreviations: ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, 











































































Abbreviations: FUP, follow-up; HBV, hepatitis B virus; HCV, hepatitis C virus. 
 
 





Patients without HBV or HCV
n = 22‘910
HCV or HBV positive at 
baseline or during FUP
n = 19‘618









Other than liver-related death
n = 1047
